Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
NCT00313768
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2009
Locations: Pfizer Investigational Site, Knoxville, Tennessee +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
NCT00251095
Terminated
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2009
Locations: Chattanooga Oncology & Hematology Associates, PC, Chattanooga, Tennessee +1 locations
Conditions: Breast Neoplasm
Register for Updates
CPG 7909 Injection in Non-Small Cell Lung Cancer
NCT00070629
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: The Family Cancer Center, Collierville, Tennessee
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
Completed
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2008
Locations: The West Clinic, Memphis, Tennessee +1 locations
Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Register for Updates
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
NCT00569751
Completed
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2008
Locations: Baptist Heart Institute, Knoxville, Tennessee +1 locations
Conditions: Cardiovascular Disease, de Novo Coronary Lesions
Register for Updates
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: Chattanooga GYN-Oncology, Chattanooga, Tennessee +1 locations
Conditions: Ovarian Neoplasm
Register for Updates
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00025688
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: East Tennessee Oncology/Hematology, P.C., Knoxville, Tennessee +1 locations
Conditions: Breast Cancer
Register for Updates
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
NCT00191672
Completed
The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including patients that have been treated with prior taxane therapy. Overall responses have ranged from 30% to 79%. The major side effects of the combination chemotherapy have been neutropenia, anemia, asthenia, neuropathy, nausea, mucositis, and neutropenic fever
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2007
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee
Conditions: Breast Neoplasms
Register for Updates